- Home
- ABVE vs AGEN Comparison
ABVE vs AGEN Comparison
Compare ABVE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVE
- AGEN
- Stock Information
- Founded
- ABVE 2019
- AGEN 1994
- Country
- ABVE Canada
- AGEN United States
- Employees
- ABVE N/A
- AGEN N/A
- Industry
- ABVE Packaged Foods
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABVE Consumer Staples
- AGEN Health Care
- Exchange
- ABVE Nasdaq
- AGEN Nasdaq
- Market Cap
- ABVE 108.5M
- AGEN 126.8M
- IPO Year
- ABVE N/A
- AGEN 2000
- Fundamental
- Price
- ABVE $2.58
- AGEN $4.57
- Analyst Decision
- ABVE
- AGEN Buy
- Analyst Count
- ABVE 0
- AGEN 2
- Target Price
- ABVE N/A
- AGEN $14.50
- AVG Volume (30 Days)
- ABVE 2.0M
- AGEN 477.2K
- Earning Date
- ABVE 01-01-0001
- AGEN 11-10-2025
- Dividend Yield
- ABVE N/A
- AGEN N/A
- EPS Growth
- ABVE N/A
- AGEN N/A
- EPS
- ABVE N/A
- AGEN N/A
- Revenue
- ABVE $213,446,206.00
- AGEN $106,829,000.00
- Revenue This Year
- ABVE N/A
- AGEN $60.49
- Revenue Next Year
- ABVE N/A
- AGEN N/A
- P/E Ratio
- ABVE N/A
- AGEN N/A
- Revenue Growth
- ABVE N/A
- AGEN N/A
- 52 Week Low
- ABVE $0.25
- AGEN $1.38
- 52 Week High
- ABVE $6.56
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- ABVE 47.78
- AGEN 62.24
- Support Level
- ABVE $1.84
- AGEN $4.11
- Resistance Level
- ABVE $2.47
- AGEN $4.49
- Average True Range (ATR)
- ABVE 0.38
- AGEN 0.29
- MACD
- ABVE 0.00
- AGEN 0.04
- Stochastic Oscillator
- ABVE 55.03
- AGEN 87.02
About ABVE Above Food Ingredients Inc. Common Stock
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).